Nigeria

Resilience System


You are here

Vaccinations

WHO warns omicron poses 'very high' global risk as variant spreads

LONDON — The global risk of the new omicron variant is “very high,” the World Health Organization said Monday, as more countries reported cases of the variant, sparking worldwide concern that there is more pandemic suffering ahead.

In response to the spike in cases, an increasing number of nations are tightening their borders despite pleas for caution and outbursts of dismay from some. 

Problem, Solution, SitRep, or ?: 

vaccine makers race to counter the new COVID-19 omicron variant

A new strain of COVID-19 first discovered in South Africa was declared a variant of concern by the World Health Organization on Friday. Here's how the pharmaceutical industry plans to address the latest coronavirus curve ball.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

WHO statement on clasification Classification of Omicron : SARS-CoV-2 as Variant of Concern

WHO statement:

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

The Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) is an independent group of experts that periodically monitors and evaluates the evolution of SARS-CoV-2 and assesses if specific mutations and combinations of mutations alter the behaviour of the virus. The TAG-VE was convened on 26 November 2021 to assess the SARS-CoV-2 variant: B.1.1.529.

The B.1.1.529 variant was first reported to WHO from South Africa on 24 November 2021. The epidemiological situation in South Africa has been characterized by three distinct peaks in reported cases, the latest of which was predominantly the Delta variant. In recent weeks, infections have increased steeply, coinciding with the detection of B.1.1.529 variant. The first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021.

Problem, Solution, SitRep, or ?: 

SARS-CoV-2 antibody levels predict COVID vaccine efficacy, study finds

 

SARS-CoV-2 antibody concentrations predict COVID-19 vaccine effectiveness, with higher levels correlating with greater protection, according to an ongoing US phase 3 clinical trial yesterday in Science.

A team led by researchers from Fred Hutchinson Cancer Research Center in Seattle evaluated 30,420 adult recipients of the Moderna mRNA COVID-19 vaccine at 99 centers for neutralizing and binding antibodies as correlates of risk for, and protection against, infection.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Vaccinations
howdy folks
Page loaded in 1.121 seconds.